ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

Organ Systems Meeting Canceled

November 19, 1982

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980

Hammer Signs $2.5 Mil. Check To NCI Fro Stop Cancer Campaign

February 2, 1990

Oral Capecitabine Equal To 5FU-Leucovorin In Adjuvant Stage III Colon Cancer Treatment

June 25, 2004

Advisors tell NCI to rethink contracts for clinical trials cooperative group tissue banks

November 21, 2003

In Brief: “The Journal” to Mae its Appearance In Jan., With Wittes As Editor; Manuscripts Solicited

October 16, 1987